No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Journal of hepatology | 2018-12-01 | PMID 30098373
Sarrazin Christoph, Cooper Curtis L, Manns Michael P and 16 more
